Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)

[1]  L. Kolonel,et al.  Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) , 1998, Cancer Causes & Control.

[2]  K. Helzlsouer,et al.  Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States) , 1995, Cancer Causes & Control.

[3]  P. Tuohimaa,et al.  Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands , 2000, International journal of cancer.

[4]  K. Burnstein,et al.  The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  B. Lund,et al.  Testosterone and Andropause: The Feasibility of Testosterone Replacement Therapy in Elderly Men , 1999, Pharmacotherapy.

[6]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[7]  T. Tammela,et al.  Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate , 1998, Journal of Steroid Biochemistry and Molecular Biology.

[8]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  M. Holick,et al.  Redefining vitamin D insufficiency , 1998, The Lancet.

[10]  G. Siegal,et al.  1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  M. Stampfer,et al.  Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  M. Anver,et al.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. , 1995, Cancer research.

[13]  Schwartz Gg,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994 .

[14]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[15]  R. Bahnson,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994, Anticancer research.

[16]  E. Corder,et al.  Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[18]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[19]  D. Bikle.  Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. , 1992, Endocrine reviews.

[20]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[21]  B. Hulka,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990, Anticancer research.

[22]  H. Koeffler,et al.  The role of the vitamin D endocrine system in health and disease. , 1989, The New England journal of medicine.

[23]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[24]  R. Mason,et al.  Stability of vitamin D metabolites in human blood serum and plasma. , 1981, Clinical chemistry.

[25]  M. Haussler,et al.  Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. , 1976, The Journal of clinical investigation.